Dopamine dysregulation is central to the pathogenesis of diseases with major psychosis, but its molecular origins are unclear. In an epigenome-wide investigation in neurons, individuals with schizophrenia and bipolar disorder showed reduced DNA modifications at an enhancer in IGF2, which disrupted the regulation of the dopamine synthesis enzyme tyrosine hydroxylase and striatal dopamine levels in transgenic mice. Epigenetic control of this enhancer may be an important molecular determinant of psychosis.
correlated with those of synaptic development genes (BrainSpan; p < 0.001; resampling; Supplementary Fig. 2b ). Furthermore, 13 of the 18 differentially-methylated regions demonstrated significant genetic-epigenetic interactions in cis (FDR < 0.05; genotypes from Infinium PsychArray-24; 36 of 56 CpG probes in regions; 2,212 of 13,552 tested SNPs) (Fig. 1c , and Supplementary Table 7) . Additionally, one differentially-methylated region at the HLA locus demonstrated significant genetic-epigenetic interactions with known genetic risk factors for schizophrenia (FDR < 0.05; 4,373 SNPs tested; Supplementary Table 8) . Therefore, neurons in major psychosis show significant changes in DNA modifications, some of which are associated with genetic state. These converge on transcriptional changes that affect early development, impair synaptic activity, and raise immune responses.
Notably, two of the top differentially modified regions in major psychosis neurons were located at the 3' end of the IGF2 gene (Šidák p < 10 -3 ) ( Fig. 2a ; Supplementary Table  2a ). Both schizophrenia and bipolar patients were consistently hypomethylated at the IGF2 locus, relative to controls (3-9% mean probe-level hypomethylation; Fig. 2b ). Hypomethylation at IGF2 was even observed in neurons of unmedicated major psychosis patients ( Supplementary Fig. 3 ). The effect of disease on average IGF2 modification remained significant after controlling for age, sex, PMI, smoking status, medication, and first two genetic principal components (nested model ANOVA, p < 0.02; Supplementary Fig. 3 ), as well as in an analysis limited to individuals of European ancestry (Šidák p < 0.001; Supplementary Table 2b) . We then fine-mapped DNA modifications at the IGF2 genomic area (~161 kb) in neurons, using a targeted bisulfite sequencing assay (n=4 cases, 3 controls). This analysis confirmed the significant hypomethylation of the IGF2 region in neurons of major psychosis cases (p < 10 -4 , mixed effects model; Fig. 2c , Supplementary Table 9 ). We did not find evidence of cis-acting genetic-epigenetic effects for any of the probes in the differentially methylated IGF2 region (FDR > 0.05; Supplementary Table 10) . We also did not find evidence that cases and controls differed in allele-specific expression of IGF2 ( Supplementary Fig. 4 ).
The hypomethylated IGF2 locus in major psychosis overlapped an enhancer in the adult frontal cortex ( Fig. 2a ; data from NIH Roadmap). Furthermore, in neurons derived from olfactory neuroepithelium, histone marks characteristic of enhancers (H3K4me1; H3K27ac) were present in schizophrenia patients, but depleted in controls (data from PsychENCODE; Fig. 2a ). Assessment of chromatin interactions in the prefrontal cortex by analysis of Hi-C data revealed that this enhancer targets the tyrosine hydroxylase gene promoter (Fig. 3a) . Tyrosine hydroxylase is the rate-limiting enzyme for the production of the neurotransmitter dopamine. Dopamine dysregulation in the cortex and striatum of both patients with schizophrenia and bipolar disorder is centrally involved in the cognitive and psychotic symptoms 8, 9 . Reduced DNA modifications at the IGF2 enhancer was associated with elevated levels of TH protein levels in the human frontal cortex (p<0.05; Fig. 3b ), supporting the hypothesis that this enhancer modulates dopamine synthesis. We then examined transgenic mice carrying an intergenic Igf2 enhancer deletion. In the striatum, inactivation of the Igf2 enhancer led to a decrease in TH protein levels and in dopamine (p<0.05; Fig. 3c and 3d) ; this effect was not observed in the frontal cortex ( Supplementary Fig. 5 ). These data collectively suggest that in schizophrenia and bipolar disorder, epigenetic disruption of enhancer activity at the IGF2 locus in neurons leads to abnormalities in dopaminergic signaling. Hypomethylation of the enhancer at IGF2 may be an important contributor to pathogenesis of psychotic symptoms.
In sum, we have identified an increase in permissive epigenetic marks at an enhancer regulating the TH gene in neurons of patients with major psychosis. Enhancer-mediated upregulation of TH causing higher striatal dopamine synthesis would augment the risk for psychosis 8 . Interestingly, in patients, the progressive loss of prefrontal cortex volume closely parallels the development of psychosis 10, 11 . Imaging studies of at-risk individuals show greater prefrontal cortical volume loss in individuals that transition to psychosis compared to those remaining healthy 11 . The severity of psychotic symptoms is also associated with structural alterations in the cortex 12 . In the brain, IGF2 promotes synapse development, spine maturation, and memory formation [13] [14] [15] [16] , signifying that normal IGF2 activation is required for healthy neuronal architecture. Recently, IGF2 was found to be the top downregulated gene in the schizophrenia prefrontal cortex in the large CommonMind consortium RNA-sequencing study 17 . Loss of DNA modification at the IGF2 locus has been associated with decreased IGF2 mRNA levels in early development 18 , and risk factors for schizophrenia; prenatal exposure to famine 19 and reduced brain weight 20 . Similarly, our transcriptome analysis found a downregulation of genes affecting synaptic transmission and interacting with IGF2. Therefore, in neurons of major psychosis patients, epigenetic changes that facilitate the recruitment of the enhancer at IGF2 for activation of the TH gene, may impede IGF2 regulation in tandem. We propose a model in which improper epigenetic control of an IGF2 enhancer simultaneously contributes to dopamine-mediated psychotic symptoms and synaptic structural deficits in major psychosis.
oversee the project. The manuscript was written by S.P. and V.L., and commented on by all authors. Isolation of neuronal nuclei using a flow cytometry Neuronal nuclei were separated using a flow cytometry-based approach, similar to as previously described 1, 2 . Human brain tissue (250 mg) for each sample was minced in 2 mL PBSTA (0.3 M sucrose, 1X phosphate buffered saline (PBS), 0.1% Triton X-100). Samples were then homogenized in PreCellys CKMix tubes with a Minilys (Bertin Instruments) set at 3,000 rpm for three 5 sec intervals, 5 min on ice between intervals. Samples homogenates were filtered through Miracloth (EMD Millipore), followed by a rinse with an additional 2 mL of PBSTA. Samples were then placed on a sucrose cushion (1.4 M sucrose) and nuclei were pelleted by centrifugation at 4,000 × g for 30 min 4°C using a swinging bucket rotor. For each sample, the supernatant was removed and the pellet was incubated in 700 μ l of 1X PBS on ice for 20 min. The nuclei were then gently resuspended and blocking mix (100 μ l of 1X PBS with 0.5% BSA (Thermo Fisher Scientific) and 10% normal goat serum (Gibco) was added to each sample. NeuN-488 (1:500; Abcam) was added and samples were incubated 45 min at 4°C with gentle mixing. Immediately prior to flow cytometry sorting, nuclei were stained with 7-AAD (Thermo Fisher Scientific) and passed through a 30 μ M filter (SystemX). Nuclei positive for 7-AAD and either NeuN+ (neuronal) or NeuN-(non-neuronal) were sorted using an Influx (BD Biosciences) at the Faculty of Medicine Flow Cytometry Facility at the University of Toronto (Toronto, ON, Canada). Approximately 1 million NeuN+ nuclei were sorted for each sample. Immediately, after sorting nuclei were placed on ice and then precipitated by raising the volume to 10 mL with 1X PBS and adding 2 mL 1.8 M sucrose, 50 μ l 1M CaCl 2 and 30 μ l Mg(Ace) 2 and centrifugation at 1,786 × g for 15 min at 4°C. The supernatant was removed from NeuN+ and NeuN-samples and pellets were stored at -80°C. Genomic DNA from each NeuN+ and NeuN-fraction of each sample was isolated using standard phenol-chloroform extraction methods.
Online Methods

Human brain samples
Genome-wide DNA methylation analysis
Whole-genome DNA methylation profiling for each sample was performed on Illumina MethylationEPIC BeadChip microarrays at The Centre for Applied Genomics (Toronto, Canada). Bisulfite converted DNA samples (n=104) were randomized across arrays (8 samples/array). Data generated from the microarrays were preprocessed with Minfi v1.19.12. Normalization was performed with noob 3 , followed by quantile normalization. All samples had sex matching that predicted from the methylome. Probes that overlapping SNPs (minor allele frequency > 5%) on the CpG or single-base extension were excluded (11,812 probes), as were probes known to be cross-reactive 4 (42, 558 probes) and those that failed detectability (P>0.01) in >20% samples (1,170 probes The top 50% probes with highest variance were used to identify differentially methylated probes (406,332 probes). For each probe, a linear model was fit using limma 5 ; in addition to diagnosis, age, sex, post-mortem interval and first two principal components of genetic ancestry were used as covariates. Ethnicity covariates were computed by PCA within plink 6, 7 . As the design included several technical replicates, these were modeled as blocking factors. Variance shrinkage was applied (limma in R). Benjamini Hochberg FDR correction was used to correct nominal p-values. Analysis was performed in R (3.3.1). To identify differentially methylated regions (DMRs) in our data, we used the Python module Comb-p 8 to group spatially correlated differentially methylated probes (seed p-value of 0.01 to start a region, at a maximum distance of 500bp in each brain tissue). The input data was a sorted BED with a column for p-value from single-probe tests. DMR p-values were corrected for multiple testing using Šidák correction.
Targeted bisulfite sequencing at IGF2 locus DNA methylation at the IGF2 and surrounding genomic area (161 kb) was captured using the SeqCap Epi Enrichment System (Roche). Biotinylated long oligonucleotide probes targeting 450 sites at the extended IGF2 locus (unique, non-repetitive genome) were custom designed by Roche NimbleGen. Library preparation was performed following manufacturer instructions. Briefly, gDNA (500 ng) of each sample (n= 4 cases and 3 controls, in addition 4 technical replicate samples) were fragmented (~ 200 bp), end repaired and ligated to barcoded adapters using the KAPA Library Preparation kit (Kapa Biosystems) and SeqCap Adapter Kit A and B (Roche) . Bisulfite conversion of the adapter ligated DNA, followed by column purification, was performed with the EZ DNA Methylation Lightning kit (Zymo). The bisulfite converted DNA for each sample was then amplified by ligation mediated PCR (95°C 2 min, 10 cycles of [98°C 30 sec, 60°C 30 sec, 72°C 4 min], 72°C 10 min, 4°C hold) followed by purification with Agencourt AMPure XP beads (Beckman Coulter). Sample quality was verified on Bioanalyzer (Agilent) and quantity was determined with a NanoDrop spectrophotometer (Thermo Fisher Scientific). Equimolar amounts of each sample were then combined into a single pool. The IGF2 target region was captured by hybridizing the amplified bisulfite converted DNA pool (1 μ g) to the probe library (Roche), as directed by manufacturer. Enrichment and recovery of captured bisulfite-converted DNA was completed by binding to magnetic beads and subsequent wash steps using the SeqCap Pure Capture Bead kit and the SeqCap Hybridization and Wash kit (Roche). The captured DNA was then amplified by ligation mediated PCR (98°C 45 sec, 11 cycles of [98°C 15 sec, 60°C 30 sec, 72°C 30 sec], 72°C 1 min) followed by purification with Agencourt AMPure XP beads (Beckman Coulter). Library quality and quantity was assessed using a combination of Agilent DNA High Sensitivity chip on a Bioanalyzer (Agilent Technologies), Qubit dsDNA HS Assay kit on a Qubit 3.0 fluorometer (Thermo Fisher Scientific), and Kapa Illumina Library Quantification qPCR assays (Kapa Biosystems). DNA sequencing was performed on an Illumina HiSeq 2500 on Rapid Run mode with all samples run on both sequencing lanes.
Data were processed using the pipeline recommended by the manufacturer 9 . Trimmomatic 10 was used to trim read adapter sequences and BSMAP 11 was used to align reads to the GRCh38/hg38 genome build. The genome index consisted of reference chromosome sequences and the lambda phage genome (https://www.ncbi.nlm.nih.gov/nuccore/215104). Following alignment, reads were pooled across the two lanes. The merged set of reads was separated into those aligning to top and bottom strand, duplicates were removed with Picard, and then matching read pairs were merged. Samtools 12 was used to exclude reads that were not properly paired or were unmapped. Bamutils were used to clip overhanging reads that distort methylation estimates. Methratio.py in BSMAP computed the percent methylation at the base level.
meQTL analysis
SNPs in each sample (n=104) were determined using the Infinium PsychArray-24 processed by The Centre for Applied Genomics (Toronto, Canada). Samples were randomized across SNP arrays. LiftOver was used to convert genotypes to the GRCh37/hg19 build. Quality control was performed as described 13 . SNPs with a minor allele frequency < 0.05, those with HWE p < 10 -6 and those missing in >1% samples were excluded. Where pairs of individuals had relatedness (Identity By State; IBS) > 0.185, one was excluded. Samples with < 90% SNPs genotyped and those with outlier heterozygosity were excluded. 96 samples passed these filters and were used for meQTL analysis. PCA for EWAS and meQTL analysis was extracted using plink on study samples. Continental genetic ancestry was ascertained by MDS using HapMap3 as a reference population 14 . For European-specific EWAS, Europeans were defined as individuals with MDS 1 and 2 lying within 3 standard deviations of the mean defined by the CEU population in the HapMap3 reference panel. For meQTL analysis and allelespecific expression analysis, we first imputed genotype data using Check-bim and the Michigan Imputation Server 15 (Eagle v2.3 16 ; 1000G 17 Phase 3 v5; Population:ALL). SNPs with INFO score > 0.7 were retained.
For cis e-QTL inference, SNPs within +/-500 kb of CpG probes in differentiallymethylated regions were tested. For trans e-QTL inference, SNPs from schizophrenia GWAS study 18 (SNPs with nominal p < 10 -9 ), and SCZ "credible" SNPs were included 18, 19 . Only SNPs with ≥ 10 individuals per genotype were tested. A linear regression was used to assess the effect of genotype on methylation, with sex, diagnosis, age, and the first two genetic principal components as covariates. Methylation for technical replicates was averaged, and where technical replicates existed for genotype, the first replicate was used. Benjamini Hochberg correction was applied for multiple testing.
Gene expression profiling by RNA-seq Brain tissue samples (n=34 human samples) were lysed using QIAzol Lysis Reagent (Qiagen) and homogenized with a TissueLyser (Qiagen). Total RNA from each sample was isolated using the RNeasy Plus Universal Mini kit (Qiagen) according to manufacturer's instructions and included an enzymatic DNase (Qiagen) digestion step. RNA quality was measured on a 2100 Bioanalyzer (Agilent) and quantity was determined with a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). RNA samples had a RIN quality score >7 and proceeded to RNA-seq library preparation (RIN between 7.1 to 9.4 for all samples). Libraries were prepared by the Van Andel Genomics Core from 300 ng of total RNA using the KAPA RNA HyperPrep Kit with RiboseErase (v1.16) (Kapa Biosystems). RNA was sheared to 300-400 bp. Prior to PCR amplification, cDNA fragments were ligated to Bio Scientific NEXTflex Adapters (Bioo Scientific). Quality and quantity of the finished libraries were assessed using a combination of Agilent DNA High Sensitivity chip (Agilent Technologies, Inc.), QuantiFluor® dsDNA System (Promega Corp.), and Kapa Illumina Library Quantification qPCR assays (Kapa Biosystems). Individually indexed libraries were pooled, and 75 bp paired-end sequencing was performed on an Illumina NextSeq 500 sequencer, with all libraries run across 3 flowcells. Base calling was done by Illumina NextSeq Control Software (NCS) v2.0 and output of NCS was demultiplexed and converted to FastQ format with Illumina Bcl2fastq v1.9.0. Trimgalore (v0.11.5) was used for adapter removal prior to genome alignment. STAR 20 (v2.3.5a) index was generated using Ensemble GRCh38 p10 primary assembly genome and the Gencode v26 primary assembly annotation. Read alignment was performed using a STAR two-pass mode. Gene counts matrix was imported into R (3.4.1) and low expressed genes (counts per million (CPM) < 1 in all samples) were removed prior to differential expression in EdgeR. Gene counts were normalized using the trimmed mean of M-values, fitted in a generalized linear model and differentially tested using a likelihood ratio test. The generalized linear model contained covariates age, sex, post mortem interval and neuronal cell composition. Cell-type compositions for each sample was accessed using CIBERSORT 21 on normalized sample counts against cell-type specific markers (see below), identifying the proportion of neurons in each samples. Benjamini Hochberg correction was used to adjust for multiple testing.
Our RNA-seq analysis corrected for the proportion of neuronal cells in each sample. Neuronal cell proportions were determined by CIBERSORT 21 (http://cibersort.stanford.edu), which involved a gene signature matrix derived from single cell RNA-seq measures in adult human brain cells (signature matrix 22 ; source 23 ). Because major psychosis is characterized by a loss of synaptic density, we excluded genes encoding synaptic proteins (Genes2Cognition database 24 ; lists L00000009, L00000016, L00000012) from the gene signatures. 135 synapse-associated genes were excluded, leaving 768 genes in the deconvolution analysis. CIBERSORT was run (100 permutations), and the inferred proportion of neurons was used as a covariate for differential expression.
For allele specific expression (ASE) analysis, we used Samtools and Picard to prepare RNAseq BAM files for ASE read counting. ASEReadCounter was used to count allelespecific transcript counts. Allelic imbalance was defined as |0.5-REF_COUNT/(REF_COUNT+ALT_COUNT)|, and only sites with one or more heterozygous alleles were included.
Pathway enrichment analysis
Pathways affected by the DNA methylation and transcriptomic changes in major psychosis were determined. For DNA methylation data, probes were mapped to genes if they overlapped with [TSS-1 kb, TES]. Gencode 25 v27 (liftOver to GRCh37) were used for gene extents. The pathway file was the same as that used for RNA pathway analysis; pathways with 10-500 genes were included. For each pathway, a hypergeometric test was performed comparing the proportion of foreground probes (p < 0.05 from DMR analysis) to background probes (all probes tested for DMRs). Benjamini-Hochberg correction was performed to adjust for multiple testing.
For gene expression data, gene set enrichment analysis (GSEA 26 ) was performed (1000 permutations) to identify the potentially dysregulated pathways. Pathway definitions were aggregated from HumanCyc 27 
Igf2 enhancer deletion in mice
A 4.9 kb-long DNA fragment (chr7: 149,796,331-149,801,250 in mm9) was deleted from the intergenic region of H19 and Igf2 by classical ES cell gene targeting in the mouse in the 129S1 genetic background. One loxP site remained at the site of the deletion mutation after the excision of the Pgkneo positive selection cassette by crossing the targeted mutant male mouse to an Hprt-CRE transgenic female 35 . Three oligonucleotide primers, IGKOCrerecU: CGGAATGTTTGTGTGGAGAGCA; IGKOwtU: TAGGGGTCCTGAAGACGTCAG;
and IGKOCreWTL: TTGGTGTAGCACCCTGTAACCC are combined in one PCR reaction to distinguish the mutant from the wild type allele, as visualized by a 450 bp or a 350 bp long PCR product, respectively.
Mice were bred and housed in ventilated polycarbonate cages, and given ad libitum sterile food (LabDiet 5021) and water. Adult mice were housed by sex in groups of 2-5 littermates. The vivarium was maintained under controlled temperature (21°C±1°C) and humidity (50-60%), with a 12-h diurnal cycle (lights on: 0700-1900). Approximately equal numbers of male and female were tested, and no sex differences were detected (in all Western blotting and HPLC experiments). No animals were excluded from the study. Wild-type (+/+) and homozygote knock-out (Igf2 enh-/-) adult mice (~2.5 months old) were tested, and sample sizes were comparable to other studies of Igf2 mutant mice 36, 37 . All animal procedures were approved by the Institutional Animal Care Committee of the Van Andel Research Institute and complied with the requirements of the Institutional Animal Care and Use Committee (AUP # PIL-17-10-010).
Immunoblotting
All tissue preparation procedures were performed on ice. Frozen tissue samples weighing ~20 mg were sonicated in 500 µl of RIPA buffer (10 mM Tris-HCl pH 8, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, protease inhibitor cocktail from Roche, and 1 mM EDTA) and incubated for 1 h on ice with mixing. The samples were then centrifuged at 22,000 × g for 30 min. Protein content of the supernatant was determined using BCA assay (Thermo Fisher Scientific) and then diluted in SDS-PAGE sample buffer (Biorad) to yield 20 µg protein per lane. Samples were separated on 4-20% SDS-PAGE gels (Thermo Fisher Scientific) and blotted onto 0.22 µm PVDF membranes (Thermo Fisher Scientific) for 2 h at a constant 20 V using xCell II blot module (Thermo Fisher Scientific). Membranes were blocked in TBST (50 mM Tris-HCl pH 7.6, 150 mM NaCl, and 1% tween-20) containing 5% non-fat dry milk (Bio-Rad) for 1 h at room temperature. Membranes were then incubated with blocking buffer containing primary antibodies: tyrosine hydroxylase (TH, PelleFreez Biologicals, AR), NeuN (Cell Signaling), internexin neuronal intermediate filament protein (INA, Sigma), and actin (Millipore) diluted 1:1000 overnight at 4⁰C. Membranes were washed three times for five minutes with TBST and probed with the appropriate HRP-conjugated anti-igg antibodies according to manufacturers recommended protocol. Blots were then washed three times for 5 min with TBST and imaged using west pico ECL reagent (Thermo Fisher Scientific).
Quantification of dopamine levels by high performance liquid chromatography (HPLC)
All tissue preparation procedures were performed on ice. Frozen tissue samples weighing between 5-20 mg were sonicated in 100-300 µl of 0.2 M perchloric acid (Sigma). The sample was centrifuged at 22,000 x g for 30 min and the resulting supernatant was filtered using 0.22 µM cellulose acetate filter (Costar). The filtered supernatant was separated using the HTEC-500 HPLC system (Eicom) with the SC-30DS reverse phase separation column (Eicom) and electrochemical detector. Samples were separated in mobile phase consisting of 0.1 M citrate acetate pH 3.5, 20% methanol, 220 g/L sodium octane sulfonate, and 5 mg/L EDTA-Na. The samples were then compared to known standards of dopamine (Sigma), homovinillic acid (HVA), and 3,4-Dihydroxyphenylacetic acid (DOPAC). The pellet was dissolved in 0.5 mL of 1 M NaOH for 10 min at 90⁰C, and the resulting protein concentration determined by BCA assay. The final values were calculated as ng analyte per µg protein.
Lifestyle factors
FDA-approved antipsychotics were collected from the literature (https://www.fda.gov/Drugs/DrugSafety/ucm243903.htm, 38 ), including generic and brand names. Patient medication information was computationally searched for keyword matches from this list to identify drugs used by individuals; the mood stabilizers lithium and valproic acid were added to this list. Where no match was found, antipsychotic status was set to "none". Analysis divided patients into those who ever had antipsychotic use and those who did not. Smoking status was binarized so that any record of lifetime smoking resulted in a categorization of the sample as a smoker. Individuals with missing information were put into a separate category.
Olfactory neuroepithelial Chip-Seq. Peak calls for histone marks in DNA isolated from olfactory neuroepithelial cells (CNON) in controls and individuals diagnosed with schizophrenia were downloaded from the PsychENCODE 39 knowledge portal (https://www.synapse.org/#!Synapse:syn4590897). The average of peak intensities in biological replicates was computed using a 250bp tiling window. 
Software used for analysis
≥
10× coverage are included in the analysis. P-value from nested mixed-effects model for effect of disease, after controlling for age and sex (n=4 cases, 3 controls; technical replicates included as random effect). Base-level methylation estimates from EPIC arrays and targeted bisulfite sequencing were strongly correlated (Pearson's coefficient R=0.57, p < 10 -4 ). 
